Diabetes Treatment Safety: Adverse Events and Side Effect Evidence

Evidence related to adverse events and safety

Evidence related to adverse events, serious safety outcomes, gastrointestinal events, urinary tract infections, DKA, hyperglycemia, and treatment tolerability in diabetes studies.

Build your Evidence Workspace

Save evidence about the topics you care about.

Studies

Evidence Pairs

Strong Research Support

Relationship Confidence: 80/100

Evidence guide

What does the evidence say?

Does Semaglutide reduce incidence of adverse events?

Semaglutide may reduce incidence of adverse events.

View answer

Does Metformin affect incidence of adverse events?

Current evidence does not establish a clear direction of effect for incidence of adverse events with Metformin.

View answer

Does Metformin affect incidence of gastrointestinal disorders?

Current evidence does not establish a clear direction of effect for incidence of gastrointestinal disorders with Metformin.

View answer

Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

Adverse Events and Safety evidence appears to center on Semaglutide.

Among 22 indexed studies and 7 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Semaglutide appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 10 evidence pairs - 17 studies

Why this appears here

Strong evidenceConsistent resultsPositive effect signalMultiple RCTsGenerally consistentModerate evidence

Semaglutide

10 studies

EvidenceScore™

79/100

ConsistencyScore™

60/100

Metformin

4 studies

EvidenceScore™

79/100

ConsistencyScore™

80/100

Evidence Snapshot

Studies

Interventions

Outcomes

Strong evidence signals

Mixed evidence areas

Key Findings

Key patterns and insights identified across the research landscape

Evidence signal

Metformin shows evidence for Total daily insulin dose

Metformin → Total daily insulin dose

Across 3 studies, Metformin shows a evidence signal for Total daily insulin dose.

3 studies

EvidenceScore™: 79/100

View supporting studies

Evidence signal

Semaglutide shows evidence for Adverse events incidence

Semaglutide → Adverse events incidence

Across 4 studies, Semaglutide shows a consistent evidence signal for Adverse events incidence.

4 studies

EvidenceScore™: 78.71153846153847/100

View supporting studies

Strong positive signal

Semaglutide shows strong evidence for improving Total daily insulin dose

Semaglutide → Total daily insulin dose

Across 3 studies, Semaglutide shows a consistent strong positive signal for Total daily insulin dose.

3 studies

EvidenceScore™: 76.64102564102565/100

View supporting studies

Moderate positive signal

Insulin therapy may improve Total daily insulin dose

Insulin therapy → Total daily insulin dose

Across 2 studies, Insulin therapy shows a consistent moderate positive signal for Total daily insulin dose.

2 studies

EvidenceScore™: 69/100

View supporting studies

Neutral signal

Semaglutide shows limited or neutral effect on Gastrointestinal disorders incidence

Semaglutide → Gastrointestinal disorders incidence

Across 2 studies, Semaglutide shows a consistent neutral signal for Gastrointestinal disorders incidence.

2 studies

EvidenceScore™: 69/100

View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Semaglutide is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Semaglutide

Insulin therapy

Semaglutide

10 studies

EvidenceScore™

79/100

ConsistencyScore™

60/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present

Evidence basis: 12 evidence pairs - 19 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Metformin may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Metformin

Insulin therapy

Metformin

4 studies

EvidenceScore™

79/100

ConsistencyScore™

80/100

Why this appears here

Positive effect signalLimited study volume

Evidence basis: 6 evidence pairs - 7 studies

View supporting studies

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Questions Answered by the Evidence

Does Semaglutide reduce incidence of adverse events?

Semaglutide may reduce incidence of adverse events.

Strong Evidence · Results are consistent across studies. · 4 studies · 4 RCTs

View answer

Does Metformin lower Total daily insulin dose?

Metformin may lower Total daily insulin dose.

Strong Evidence · Results are generally consistent across studies. · 3 studies · 3 RCTs

View answer

Does Semaglutide lower Total daily insulin dose?

Semaglutide appears to lower Total daily insulin dose.

Strong Evidence · Results are consistent across studies. · 3 studies · 3 RCTs

View answer

Does Semaglutide affect incidence of gastrointestinal disorders?

Current evidence does not establish a clear direction of effect for incidence of gastrointestinal disorders with Semaglutide.

Moderate Evidence · Results are consistent across studies. · 2 studies · 2 RCTs

Only a small number of supporting studies are available.

View answer

Does Insulin therapy lower Total daily insulin dose?

Insulin therapy may lower Total daily insulin dose.

Moderate Evidence · Results are consistent across studies. · 2 studies · 2 RCTs

Only a small number of supporting studies are available.

View answer

Browse all questions about Adverse Events and Safety

Overall Evidence Signals

Among 22 indexed studies and 7 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.